文献速递神经肿瘤

贝伐珠单抗联合替莫唑胺再程放疗治疗贝伐珠单抗难治性复发高级别胶质瘤的多中心前瞻性研究

A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
PubMed 文献 · J Neurooncol · 2021-10-24

全组中位OS为8.5个月,贝伐珠单抗预暴露GBM组为7.9个月;距初次放疗≥36个月者中位OS为13.3个月,优于<36个月者的7.5个月(p<0.01)。治疗耐受良好,无放射性坏死发生。

要点

  • 再程放疗联合贝伐珠单抗和替莫唑胺对贝伐珠单抗难治性复发高级别胶质瘤安全可行。
  • 距初次放疗≥36个月的患者中位OS达13.3个月,显著优于<36个月者的7.5个月。
  • 治疗耐受良好,未发生放射性坏死,生活质量评分先降后恢复至基线。

核心结论

  • 再程放疗联合贝伐珠单抗和替莫唑胺是贝伐珠单抗难治性复发高级别胶质瘤安全可行的挽救治疗。
  • 距初次放疗时间较长的患者可能从该方案中获益更大。

研究设计与样本

  • 按WHO分级(4级 vs <4级)和既往贝伐珠单抗暴露(是 vs 否)分层。
  • 治疗方案:同步整合推量放疗(增强病灶55 Gy,非增强病灶45 Gy,25次)联合贝伐珠单抗10 mg/kg每2周静脉注射和替莫唑胺75 mg/m2每日,后续维持治疗。
  • 主要终点为总生存期,生活质量采用FACT-Br和FACT-fatigue量表评估。

主要发现

  • 全组中位OS为8.5个月,贝伐珠单抗预暴露GBM组(n=36,67%)中位OS为7.9个月。
  • 距初次放疗≥36个月患者中位OS为13.3个月,<36个月者为7.5个月(p<0.01)。
  • FACT-Br和FACT-Fatigue评分在放疗期间初始下降,但恢复至治疗前基线。
  • 5例发生>3级淋巴细胞减少,2例发生>3级血小板减少。
  • 未发生影像学或临床放射性坏死。

关键数值与推荐

  • 放疗剂量:增强病灶55 Gy,非增强病灶45 Gy,25次分割。
  • 贝伐珠单抗剂量:10 mg/kg每2周静脉注射。
  • 替莫唑胺剂量:同步期75 mg/m2每日,维持期50 mg/m2每日用6周休2周。
  • 分层因素:WHO分级(4级 vs <4级)和既往贝伐珠单抗暴露(是 vs 否)。
  • 主要终点为总生存期。

临床怎么用

  • 对于贝伐珠单抗难治性复发高级别胶质瘤,可考虑再程放疗联合贝伐珠单抗和替莫唑胺作为挽救治疗。
  • 距初次放疗≥36个月的患者可能更适合接受该联合方案。
  • 治疗期间需监测淋巴细胞和血小板减少,但整体耐受性良好。

局限性

  • 单臂研究设计,缺乏随机对照,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Survival is dismal for bevacizumab refractory high-grade glioma patients. We prospectively investigated the efficacy of re-irradiation, bevacizumab, and temozolomide in bevacizumab-naïve and bevacizumab-exposed recurrent high-grade glioma, without volume limitations, in a single arm trial. METHODS: Recurrent high-grade glioma patients were stratified based on WHO grade (4 vs. < 4) and prior exposure to bevacizumab (yes vs. no). Eligible patients received radiation using a simultaneous integrated boost technique (55 Gy to enhancing disease, 45 Gy to non-enhancing disease in 25 fractions) with bevacizumab 10 mg/kg every 2 weeks IV and temozolomide 75 mg/m2 daily followed by maintenance bevacizumab 10 mg/kg every 2 weeks and temozolomide 50 mg/m2 daily for 6 weeks then a 2 week holiday until progression. Primary endpoint was overall survival. Quality of life was studied using FACT-Br and FACT-fatigue scales. RESULTS: Fifty-four patients were enrolled. The majority (n = 36, 67%) were bevacizumab pre-exposed GBM. Median OS for all patients was 8.5 months and 7.9 months for the bevacizumab pre-exposed GBM group. Patients ≥ 36 months from initial radiation had a median OS of 13.3 months compared to 7.5 months for those irradiated < 36 months earlier (p < 0.01). FACT-Br and FACT-Fatigue scores initially declined during radiation but returned to pretreatment baseline. Treatment was well tolerated with 5 patients experiencing > grade 3 lymphopenia and 2 with > grade 3 thrombocytopenia. No radiographic or clinical radiation necrosis occurred. CONCLUSIONS: Re-irradiation with bevacizumab and temozolomide is a safe and feasible salvage treatment for patients with large volume bevacizumab-refractory high-grade glioma. Patients further from their initial radiotherapy may derive greater benefit with this regimen.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Dixit KS, Sachdev S, Amidei C, et al. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. J Neurooncol. 2021. PMID: 34689306. doi:10.1007/s11060-021-03875-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。